Cell and Gene Therapy (CGT) is currently one of the most promising global biopharmaceutical fields, with broad prospects in the treatment of cancer, genetic diseases, rare diseases, chronic diseases, and more. Driven by technological innovation and policy dividends, China has developed into the region with the highest CGT popularity in the world. The 4th CGT Disruptive Technology Innovation Forum aims to build a multi-party communication platform focused on the CGT field, inviting industry experts, enterprise representatives, investment institution representatives, government representatives, and others to gather together to discuss the cutting-edge technologies, latest research results, and market trends in the CGT field, and promote high-quality development of the industry

On August 25th, the "4th CGT Disruptive Technology Innovation Forum" hosted by the Cell Medicine Branch of the China Food and Drug Enterprise Quality and Safety Promotion Association, the Guangzhou Development Zone Biomedical and Health Industry Promotion Association, and the Cell Technology Network was successfully held in Guangzhou. This event has received strong support from Yunpu No.1 Science and Technology Innovation Park.

Professor Chen Junhui, Head of the Cell Therapy Innovation Transformation Platform at Peking University Shenzhen Hospital and Chairman of the Cell Medicine Branch of the China Food and Drug Promotion Association, Chairman of Guangzhou Runsheng Cell Medicine Technology Co., Ltd. and Tvac ® Professor Ruan Runsheng, founder of personalized precision combined immunotherapy technology for tumors, Professor Xiao Gang, director of the Department of Laboratory Medicine at the Third Affiliated Hospital of Southern Medical University, Dr. Xia Shuqi, medical director of Zhongke Lanhua (Guangzhou) Biomedical Technology Co., Ltd., Dr. Luo Xiaoling, president of Shenzhen Mingjian Testing Professional Technology Co., Ltd., Mr. Chen Zanquan, CEO of Cell Technology Network, Dr. Xu Yanwei, director of the Office of the Cell Medicine Branch of the China Food and Drug Promotion Association, Ms. Hu Jianqiu, secretary general of the Guangzhou Development Zone Biomedical and Health Industry Promotion Association, Dr. Chen Qiaolin, chairman of Zhongke Cell, Mr. Lin Liming, founder/CEO of Bowen Biotechnology, Mr. Wei Erjian, general manager of Anxin Biotechnology, and other guests attended the event to discuss cell and health issues with representatives from participating companies. In depth exploration of research and application in the field of gene therapy.

The theme event was hosted by Hu Jianqiu, Secretary General of the Guangzhou Development Zone Biomedical and Health Industry Promotion Association. She expressed her gratitude to the attendees and introduced each guest present.

Firstly, Professor Chen Junhui, the person in charge of the innovative transformation platform for cell therapy at Peking University Shenzhen Hospital and the chairman of the Cell Medicine Branch of the China Food and Drug Promotion Association, delivered a welcome speech for this event. After the speech, Professor Chen Junhui began his first keynote speech "The Future and Challenges of CGT Industry", discussing the rapid development of CGT industry and the revolutionary changes it has brought to the medical field.

Dr. Xia Shuqi, Medical Director of Zhongke Lanhua (Guangzhou) Biomedical Technology Co., Ltd., gave a keynote speech on "Experimental and Clinical Research on Immunoecological Therapy for Cancer Treatment", discussing the essence and advantages of malaria parasite immunotherapy to address the biggest pain points in current cancer treatment: recurrence, metastasis, and drug resistance.

Chairman of Guangzhou Runsheng Cell Medicine Technology Co., Ltd. and Tvac ® Professor Ruan Runsheng, founder of personalized precision combined immunotherapy technology for tumors, gave a keynote speech on "Precision Immunotherapy for Tumors", introducing the clinical research status of precision immunotherapy for tumors and the company's product pipeline.

Professor Xiao Gang, Director of the Laboratory Department of the Third Affiliated Hospital of Southern Medical University, gave a keynote speech on "Genetic Physical Examination Helps the Development of Cell and Gene Therapy", elaborating on the application and importance of a complete set of human genetic testing.

Dr. Luo Xiaoling, President of Shenzhen Mingjian Testing Professional Technology Co., Ltd., gave a keynote speech on "CGT Product Risk Assessment and Quality Verification", sharing her professional experience and cases in CGT product risk assessment and quality verification.

After the sharing, a roundtable dialogue on the topic of "How CGT can revolutionize technological innovation" was held under the leadership of Mr. Chen Zanquan, CEO of Cell Technology Network. Dr. Chen Qiaolin, Chairman of Zhongke Cell, Mr. Lin Liming, Founder/CEO of Bowen Biotech, Mr. Wei Erjian, General Manager of Anxin Biotech, and Ms. Luo Xiaoling, President of Mingjian Testing, engaged in heated discussions around the CGT field and expressed unique insights from their respective professional perspectives.